Antiplatelet agents and anticoagulants: management of the anticoagulated surgical patient;Antiagregantes y anticoagulantes: manejo del paciente quirúrgico anticoagulado

Cirugia Espanola

Volumn 85, Issue SUPPL. 1, 2009, Pages 7-14

  Llau, Juan V ^a   Ferrandis, Raquel ^a   López Forte, Cristina ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Acenocoumarol; Aspirin; Bridge therapy; Clopidogrel; Regional anesthesia; Surgical hemorrhage; Thromboprophylaxis; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ARTICLE; HUMAN; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; THROMBOSIS;

ANTICOAGULANTS; HUMANS; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; THROMBOSIS;

EID: 67649583533     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/S0009-739X(09)71622-7     Document Type: Article

References (25)

1. Lecompte T., and Hardy J.F. Antiplatelet agents and perioperative bleeding. Can J Anaesth 53 (2006) S103-S112
2. Burger W., Chemnitius J.M., Kneissl G.D., and Rücker G. Low dose aspirin for secondary cardiovascular prevention -cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation- review and meta-analysis. J Intern Med 257 (2005) 399-414
3. Samama C.M., Bastien O., Forestier F., Denninger M.H., Isetta C., Juliard J.M., et al., The expert group. Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001 - Summary statement. Can J Anaesth 49 (2002) S26-S35
4. Campbell C.L., Smyth S., Montalescot G., and Steinhubl S.R. Aspirin dose for the prevention of cardiovascular disease: a sistematic review. JAMA 297 (2007) 2018-2024
5. Patrono C., Bachmann F., Baigent C., Bode C., De caterina R., Charbonnier B., et al. Documento de consenso de expertos sobre el uso de agentes antiplaquetarios. Rev Esp Cardiol 57 (2004) 963-980
6. Patrono C., Coller B., Fitzgerald G.A., Hirsh J., and Roth G. Platelet active drugs: the relationships among dose, effectiveness and side effects. Chest 126 Suppl (2004) S234-S264
7. Dalal A.R., D'Souza S., and Shulman R.S. Brief review: Coronary drug-eluting stents and anesthesia. Can J Anaesth 53 (2006) 1230-1243
8. Reddy P.R., and Vaitkus P.T. Risks of noncardiac surgery after coronary stenting. Am J Cardiol 95 (2005) 755-757
9. Llau JV, López C, Sapena L, Ferrandis R. Perioperative management of antiplatelet agents in noncardiac surgery. Eur J Anaesth. 2009 (En prensa).
10. Chassot P.G., Delabays A., and Spanh D.R. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 99 (2007) 316-328
11. Albaladejo P., Marret E., Piriou V., and Samama C.M. Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. Br J Anaesth 97 (2006) 580-582
12. Doukekis J.D., Berger P.B., Dunn A.S., Jaffer A.K., Spyropoulos A.C., Becker R.C., et al. The perioperative management of antithrombotic therapy. Chest 133 (2008) S299-339
13. Despotis G., Eby C., and Lublin D.M. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion 48 (2008) S2-30
14. Llau J.V., de Andrés J., Gomar C., Gómez-Luque A., Hidalgo F., and Torres L.M. Anticlotting drugs and anaesthestic and analgesic techniques: An update of the safety recommendations. Eur J Anaesth 24 (2007) 287-298
15. Hirsh J., Warkentin T.E., Shaughnessy S.G., Anand S.S., Halperin J.L., Raschke R., et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 Suppl 1 (2001) S64-S94
16. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 337 (1997) 688-698
17. Llau J.V. Heparinas de bajo peso molecular. In: Llau J.V. (Ed). Tratado de hemostasia y medicina transfusional perioperatoria (2003), Arán, Madrid 133-142
18. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E. The pharmacology and management of the vitamin K antagonists. Chest 126 (2004) S204-S233
19. Llau J.V., de Andrés J., Gomar C., Gómez-Luque A., Hidalgo F., and Torres L.M. Guía clínica de fármacos inhibidores de la hemostasia y anestesia regional neuroaxial. Rev Esp Anestesiol Reanim 52 (2005) 413-420
20. Keam S.J., and Goa K.L. Fondaparinux sodium. Drugs 62 (2002) 1673-1685
21. Geerts W.H., Pineo G.F., Heit J.A., Bergquist D., Lassen M., Colwell C.W., et al. Prevention of venous thromboembolism. Chest 126 (2004) S338-S400
22. Kozek-Langenecker S.A., Fries D., Gütl M., Hofmann N., Innerhofer P., Kneifl W., et al. Lokoregionalanästhesien unter gerinnungshemmender Medikation. Anaesthesist 54 (2005) 476-484
23. Vandermeulen E., Singelyn F., Vercauteren M., Brichant J.F., Ickx B.E., and Gautier P. Belgian guidelines concerning central neural blockade in patients with drug induced alteration of coagulation: an update. Acta Anaesthesiol Belg 56 (2005) 139-146
24. Horlocker T.T., Wedel D.J., Benzon H., Brown D.R., Enneking F.K., Heit J.A., et al. Regional anesthesia in the anticoagulated patient: Defining the risks (The Second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 28 (2003) 172-197
25. Gogarten W., van Aken H., Büttner J., Riess H., Wulf H., and Buerkle H. Rückenmarksnahe Regionalanästhesien und Thromboembolieprophylaxe / antithrombotische Medikation. Überarbeitete Leitlinien der Deustchen Gesellschaft für Anästhesiologie und Intensivmedizin. Anäst?. Intensivmed 44 (2003) 218-230